5月9日,加科思-B(01167)早盘股价上涨3.30%,报3.76港元。公司宣布自主研发的SHP2抑制剂sitneprotafib相关研究已发表于《临床肿瘤研究》期刊。研究表明,该药物与KRAS G12C抑制剂、MEK抑制剂及PD-1抗体联合使用时,显著增强抗肿瘤效果。目前,sitneprotafib已进入与戈来雷塞联用的三期临床试验阶段,成为全球首个进入该阶段的SHP2抑制剂。
Source Link5月9日,加科思-B(01167)早盘股价上涨3.30%,报3.76港元。公司宣布自主研发的SHP2抑制剂sitneprotafib相关研究已发表于《临床肿瘤研究》期刊。研究表明,该药物与KRAS G12C抑制剂、MEK抑制剂及PD-1抗体联合使用时,显著增强抗肿瘤效果。目前,sitneprotafib已进入与戈来雷塞联用的三期临床试验阶段,成为全球首个进入该阶段的SHP2抑制剂。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.